Stockreport

CorMedix announces commercial agreement with dialysis provider [Seeking Alpha]

CorMedix Inc.  (CRMD) 
NASDAQ:AMEX Investor Relations: cormedix.com
PDF CorMedix received NDA approval of DefenCath under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD) on November Recommended For You [Read more]